Three Genetic Polymorphisms of Homocysteine-Metabolizing Enzymes and Risk of Coronary Heart Disease: A Meta-Analysis Based on 23 Case-Control Studies
Three Genetic Polymorphisms of Homocysteine-Metabolizing Enzymes and Risk of Coronary Heart Disease: A Meta-Analysis Based on 23 Case-Control Studies
复制标题
DOI：
10.1089/dna.2011.1281
复制
发表时间：
2012-02-01
影响因子：
3.1
通讯作者：
Cheng, Xiaoshu
中科院分区：
文献类型：
--
作者：
Chen, Ling;Liu, Liu;Cheng, Xiaoshu
许多流行病学研究探讨了编码同型半胱氨酸代谢酶（蛋氨酸合成酶[MTR] A2756 G、蛋氨酸合成酶还原酶[MTRR] A66 G和N-5，N-10-亚甲基四氢叶酸还原酶[MTHFR] A1298 C）的3种基因多态性与冠心病（CHD）风险的关系，但尚未获得结论性结果。因此，我们对23项病例对照研究进行了荟萃分析。比值比（OR）和95%置信区间（95%CI）用于检查关联的强度。在这些主要研究中，22项研究是针对欧洲人的，一项研究关注亚洲人的MTR A2756 G多态性。MTR A2756 G多态性的联合分析结果表明，G等位基因与CHD和心肌梗死（MI）的风险增加相关，尤其是在欧洲人中（GG vs. AA治疗CHD：OR [95% CI] = 1.63 [1w.18-2.25]，p（z检验）= 0.001，p（异质性）= 0.274; GG + AG vs. AA治疗MI：OR [95% CI] = 1.44 [1.08-1.93]，p（z检验）= 0.014，p（异质性）= 0.611）。此外，根据基于人群的病例对照研究（PCC），G等位基因也与CHD风险较高相关（GG vs. AA：OR [95% CI] = 1.75 [1.24-2.49]，p（z检验）= 0.002，p（异质性）= 0.316）。结果提示MTRR A66 G多态性与欧洲人CHD的风险无关（AA vs. GG：OR [95%CI] = 1.07 [0.59- 1.94]，p（z-检验）= 0.831，p（异质性）
Many epidemiological studies have explored the relationships between three genetic polymorphisms of genes encoding homocysteine-metabolizing enzymes (methionine synthase [MTR] A2756G, methionine synthase reductase [MTRR] A66G, and N-5,N-10-methylenetetrahydrofolate reductase [MTHFR] A1298C) and risk of coronary heart disease (CHD), but no conclusive results were obtained. Therefore, we performed a meta-analysis of 23 case-control studies. Odds ratio (OR) and 95% confidence interval (95% CI) were used to examine the strength of the associations. Among those primary studies, 22 studies were for Europeans, and one study focused on the MTR A2756G polymorphism in Asians. The results of combined analyses of the MTR A2756G polymorphism suggested that the G allele was associated with increased risk of CHD and myocardial infarction (MI) especially for Europeans (GG vs. AA for CHD: OR [95% CI] = 1.63 [1w.18-2.25], p(z-test) = 0.001, p(heterogeneity) = 0.274; GG + AG vs. AA for MI: OR [95% CI] = 1.44 [1.08-1.93], p(z-test) = 0.014, p(heterogeneity) = 0.611). In addition, the G allele was also associated with higher risk CHD based on population-based case-control studies (PCC) (GG vs. AA: OR [95% CI] = 1.75 [1.24-2.49], p(z-test) = 0.002, p(heterogeneity) = 0.316). The results suggested that the MTRR A66G polymorphism was not associated with risk of CHD for Europeans (AA vs. GG: OR [95% CI] = 1.07 [0.59- 1.94], p(z-test) = 0.831, p(heterogeneity)